In yesterday’s Wall Street session, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) shares traded at $0.33, down -15.32% from the previous session.
As of this writing, 2 analysts cover Adial Pharmaceuticals Inc. (NASDAQ:ADIL). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $0.38, this indicates a potential upside of 1478.95 percent. ADIL stock price is now 18.54% away from the 50-day moving average and 2.34% away from the 200-day moving average. The market capitalization of the company currently stands at $9.42M.
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
With the price target of $5, Maxim Group recently initiated with Buy rating for Adial Pharmaceuticals Inc. (NASDAQ: ADIL).
Insiders disposed of 166,667 shares of company stock worth roughly $55000.11 over the past 1 year. A total of 4.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ADIL stock. A new stake in Adial Pharmaceuticals Inc. shares was purchased by MANCHESTER CAPITAL MANAGEMENT LLC during the first quarter worth $392,000. ENVESTNET ASSET MANAGEMENT INC invested $4,000 in shares of ADIL during the first quarter. In the first quarter, AMERICAN PORTFOLIOS ADVISORS acquired a new stake in Adial Pharmaceuticals Inc. valued at approximately $2,000. In total, there are 26 active investors with 7.20% ownership of the company’s stock.
Wednesday morning saw Adial Pharmaceuticals Inc. (NASDAQ: ADIL) opened at $0.3651. During the past 12 months, Adial Pharmaceuticals Inc. has had a low of $0.20 and a high of $2.08. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.60, and a quick ratio of 1.60. The fifty day moving average price for ADIL is $0.2748 and a two-hundred day moving average price translates $0.3187 for the stock.
The latest earnings results from Adial Pharmaceuticals Inc. (NASDAQ: ADIL) was released for Mar, 2023.
Adial Pharmaceuticals Inc.(ADIL) Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
